A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome
Sign Up to like & getrecommendations! Published in 2022 at "JCI Insight"
DOI: 10.1172/jci.insight.163030
Abstract: BACKGROUND Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B cell subsets; and increases… read more here.
Keywords: primary gren; gren syndrome; belimumab rituximab; sequential belimumab ... See more keywords